Published in final edited form as:

J Mol Biol. 2017 April 07; 429(7): 1045–1066. doi:10.1016/j.jmb.2017.02.012.

Cullin E3 ligase activity is required for myoblast differentiation

Jordan Blondelle¹, Paige Shapiro¹, Andrea A. Domenighetti^{2,3}, and Stephan Lange^{1,#}

¹Division of Cardiology, University of California, San Diego, CA

²Rehabilitation Institute of Chicago, Chicago, IL USA

³Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, IL

Abstract

The role of cullin E3-ubiquitin ligases for muscle homeostasis is best known during muscle atrophy, as the cullin-1 substrate adaptor atrogin-1 counts among the most well-characterized muscle atrogens. We investigated, whether cullin activity was also crucial during terminal myoblast differentiation and aggregation of acetylcholine receptors for the establishment of neuromuscular junctions *in vitro*. The activity of cullin E3-ligases is modulated through posttranslational modification with the small ubiquitin-like modifier nedd8. Using either the Nae1 inhibitor MLN4924 (Pevonedistat) or siRNA against nedd8 in early or late stages of differentiation on C2C12 myoblasts, and primary satellite cells from mouse and human, we show that cullin E3-ligase activity is necessary for each step of the muscle cell differentiation program *in vitro*. We further investigate known transcriptional repressors for terminal muscle differentiation ZBTB38, Bhlhe41 and Id1. Due to their identified roles for terminal muscle differentiation, we hypothesize that accumulation of these potential cullin E3-ligase substrates may be partially responsible for the observed phenotype. MLN4924 is currently undergoing clinical trials in cancer patients, and our experiments highlight concerns on the homeostasis and regenerative capacity of muscles in these patients who often experience cachexia.

Graphical Abstract

#correspondence should be addressed to: Stephan Lange, PhD, School of Medicine, 9500 Gilman Dr., BRF2 #1243, CA-92093 La Jolla, USA, slange@ucsd.edu, Phone: +1 (858)-822-4618.

Accession numbers

Mouse ZBTB38 mRNA accession number type ID: **NM_175537**.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

cullin; E3-ubiquitin ligase; muscle development; MLN4924

Introduction

Skeletal muscle mass represents up to 40% of the young adult body weight. Its maintenance is regulated by the equilibrium between muscle growth or physiological hypertrophy, and muscle atrophy, which is reflected on the cellular level by the balance between protein synthesis and degradation. While hypertrophy relies mainly on the activation of the PI3K-mTOR signaling pathway, immobilization, denervation, ageing or diseases such as cancer may induce muscle atrophy [1]. In muscle cells, the autophagy-lysosome and the ubiquitin-proteasome systems are the main protein degradation mechanisms [2, 3]. In particular, the ubiquitin-proteasome system (UPS) is responsible for the degradation of the majority of cytoplasmic proteins [4].

The UPS requires the tagging of substrates by ubiquitin via an enzymatic cascade [4, 5]. First, the E1-ubiquitin activating enzyme covalently attaches to ubiquitin through an ATP driven step. Once activated, ubiquitin is transferred to E2-ubiquitin conjugating enzymes. The last step requires the concerted action of an E2-enzyme and an E3-ubiquitin ligase, which transfer the ubiquitin from the E2-enzyme onto the substrate. Once poly-ubiquitylated, the substrate is targeted to the proteasome for degradation.

Cullin-RING ligases (CRL) represent the largest family of E3-ubiquitin ligases in mammalian cells [6, 7]. In order to form CRL complexes, each cullin, which forms the backbone of the E3-ligase complex, interacts modularly with RING (*Really Interesting New Gene*) domain proteins Rbx1 or Rbx2 that are in turn bound to E2-enzymes. Each member of the cullin protein family binds also to a specific subset of adaptor proteins, thereby achieving specificity for a range of cellular substrates. The activity of CRL is regulated by posttranslational modification of the cullin protein with the small ubiquitin-like protein nedd8 [6–8]. The essential role of CRL for adult muscle homeostasis has been unraveled by the discovery that nedd8 is almost exclusively expressed in muscles[9], and of the requirement of cullin-1 and its substrate adaptor atrogin-1 (MAFbx, Fbxo32), to mediate muscle atrophy [10]. However, while largely uncharacterized, there is an emerging role for other substrate adaptors for cullin-1, and CRL complexes that are formed by other cullin proteins, like cullin-3, for myogenesis and skeletal muscle development [11].

In the last twenty years, the role of cullin-RING ligases has been mainly investigated in the context of cancers, revealing a plethora of functions relevant for carcinogenesis [12, 13]. So far, many of identified CRL substrates play a role in cell cycle progression [14], such as Cyclin E [15, 16] that is a gatekeeper of the passage from the G1 phase to the S phase. Therefore, CRL became recently an attractive potential anti-cancer target [17], and the discovery of inhibitors of cullin neddylation, such as MLN4924, opened new therapeutic avenues [14]. MLN4924 is currently undergoing clinical trials for various cancer types [18, 19].

Cancer patients may develop cachexia, a deleterious wasting syndrome that is associated with muscle atrophy, and has an impact on the wellbeing of patients and on the response to the treatment. Indeed, cachexia is a devastating and often irreversible syndrome observed in up to 80% of cancer patients [20]. Most importantly, cachexia has been shown to be responsible for the death of 20% of all cancer patients [21, 22]. In mice, defects in skeletal muscle regeneration and satellite cell differentiation due to a deregulation of Pax7 expression have been demonstrated to contribute to cancer cachexia [23]. Indeed, the efficiency of muscle mass and its maintenance in cancer patients, has been used as an independent predictor of mortality in some cancers [24, 25], and should be closely monitored.

To date, no data are available regarding the effect of a loss of CRL activity on muscle cell differentiation as well as the effect of MLN4924 on muscle cells. Given the emerging role of CRL substrate adaptors in muscle development and disease [11], we decided to address the function of CRL in myogenesis and myotube formation by using MLN4924 and siRNA experiments.

Our data revealed, for the first time, that CRL activity is required for myoblast differentiation as well as for the commitment of the skeletal muscle stem cells into the myogenic differentiation program. Our data highlight that MLN4924, a CRL activity inhibitor used currently as a potential cancer therapy, has potentially negative side effects on muscle cell differentiation through, in part, the regulation of *myogenin* expression. Given the systemic delivery of MLN4924 in cancer patients during clinical trials [18, 19], our results suggest the necessity to closely monitor skeletal muscle mass and muscle regeneration in treated patients.

Results

Cullin-RING ligase inhibition prevents myotube formation

Cullin activity is known to be important during muscle atrophy, as the cullin-1 substrate adaptor atrogin-1 (MAFbx, Fbxo32) counts among the best-characterized muscle atrogens. We set out to investigate whether cullin activity is also changed during muscle differentiation, and whether there is a requirement for cullin-mediated protein degradation during myotube formation. Levels of neddylation-modified proteins at approximately 80 kDa, which can be attributed to neddylated versions of cullin-1, cullin-2, cullin-3, cullin-4A, or cullin-5, increased significantly over the first two days in differentiation, to decrease back to levels found during proliferation (Figure 1A, 1B). Intriguingly, this change on the protein

level was not mirrored on the RNA level, where total nedd8 mRNA increased more than two-fold over the same period (Figure 1C). The observed increase in neddylation is indicative of changes to cullin-activity. We further used the nedd8 activating enzyme (NAE1) inhibitor MLN4924 [26] that interferes with the activation of all cullin E3-ligases to investigate whether cullin-mediated protein degradation is required for muscle differentiation. Confluent cultures of C2C12 myoblasts were incubated in presence of 330nM MLN4924 supplemented to the differentiation medium, and allowed to differentiate for 5 days. While the vehicle treated control cells formed long, multinucleated myotubes, C2C12 cells treated with the inhibitor failed to form myotubes (Figure 1D). In order to investigate the time-point at which cullin activity is critical during myotube formation, we investigated levels of nedd8-modified proteins over the course of the muscle cell differentiation, and set up a timed inhibitor treatment experiment. This experiment also tests whether the identified peak for the neddylation of cullin proteins over the first couple of days is important for the differentiation of myoblasts into myotubes. Differentiating C2C12 cultures were treated with MLN4924 either one, two or three days after change into differentiation medium, and cultured for a total of 5 days. Differentiating cells showed a lack of myotube formation upon inhibitor treatment one or two days after differentiation. However, some myotubes were found when the inhibitor was added three days after start of differentiation (Figure 1E), as also observed when we measured the fusion index (i.e number of nuclei per myotube; Figure 1F). Accordingly, the distribution of nuclei per myotube revealed a strong accumulation of small myotubes containing 2–3 nuclei, and a severe decrease in the number of large myotubes containing >7 nuclei after 5 days of differentiation (Figure 1G). These data indicate that cullin E3-ubiquitin ligase activity is crucial at the onset of the myotube formation at around 1–2 days of differentiation, with a weaker effect at later stages. Cullin protein levels (overall band intensity) and activity (as measured by the super-shifted ‘neddylated’ cullin) return to levels observed in proliferative C2C12 cells 5 days after the start of differentiation for cullin-1 and cullin-3 (Figure 1H). Treatment with MLN4924 shows decreased or absent cullin activity, congruent with largely reduced nedd8-levels, validating the efficiency of the inhibitor on C2C12 cells (Figure 1H).

Next we investigated the dose-response for the effect of cullin inhibition on myotube formation. We treated differentiating C2C12 cells either with 30nM, 130nM, 230nM or 330nM MLN4924, or vehicle control. Microscopic brightfield and immunofluorescence images of C2C12 cells 5 days after start of differentiation indicated that as little as 130nM MLN4924 was sufficient to significantly reduce the fusion index to about 40% of control levels, with higher doses showing a more severe inhibition of myotube formation (Figures 2A, 2B, Supplemental Figure S1A). Immunoblot analysis of C2C12 cells differentiated with increasing amounts of MLN4924 also show gradual loss of 80kDa nedd8-modified proteins and sarcomeric myosin heavy chain (MyHC) expression (Figure 2C), in agreement with a decrease in fusion index (Figure 2B). To verify that the inhibition of cullin activity by MLN4924 is specific, and works through a deficiency in neddylation we used small interfering RNA (siRNA).

Proliferating C2C12 were either transfected with siRNA directed against nedd8 or a scrambled control, and allowed to differentiate for 5 days. Specific knockdown of nedd8 that results in significantly decreased cullin neddylation at approximately 80kDa was verified by

immunoblots (Figure 2D, Supplemental Figure S1B). Inhibition of cullin activity by nedd8 siRNA also led to a reduction in total ubiquitylation, as observed in immunoblot assays (Supplemental Figure S1C–D). Immunofluorescence analysis of differentiated C2C12 myotubes transfected with siRNA against nedd8 fail to form myotubes (Figure 2E, Supplemental Figure S1E), similar to MLN4924 treated cells (Figure 2A, 330nM MLN4924). The failure to form multinucleated myotubes in nedd8 siRNA transfected C2C12 is also reflected in the low fusion index measured for these cells compared to controls (Figure 2F). Analysis of myosin heavy chain expression (MyHC; Figure 2G) further validated that C2C12 transfected with siRNA against nedd8 fail to differentiate, similar to MLN4924 treated cells (Figure 2C). These data indicate that cullin activity is crucial for the formation of multinucleated myotubes, and the expression of key muscle specific genes, like sarcomeric myosin heavy chains during terminal muscle differentiation. The action of MLN4924 is specific, and inhibits muscle formation in a dose-dependent way.

Cullin inhibition prevents entry into the terminal myogenic differentiation program

Because we observed a complete loss of sarcomeric myosin heavy chain (MyHC) expression (Figure 2), we wondered whether nedd8 inhibition interferes globally with the activation of critical muscle genes, and entry into the terminal muscle differentiation program. We tested expression of muscle proteins critical for myofilament formation, like sarcomeric alpha-actinin, using immunofluorescence and immunoblot assays. While MyHC and alpha-actinin expression was upregulated in differentiating control cells, MLN4924 treated cells largely failed to express these muscle proteins, crucial for myofibrillogenesis (Figure 3A, 3B). Similarly, desmin levels in nedd8 inhibitor treated cells remain comparable to those found in undifferentiated, proliferating myoblasts (Figure 3A).

Muscle gene expression is regulated by several myogenic transcription factors, including myogenin. We tested myogenin protein levels in inhibitor treated and vehicle treated control cells, and compared them to proliferating myoblasts.

Intriguingly, myogenin protein levels in MLN4924 treated C2C12 cells remained low, comparable to proliferating myoblast cultures (Figure 3C). This result indicates that cullin activity is required to enter into the myogenic differentiation program. C2C12 cells treated with MLN4924 show low neddylation levels of cullin-proteins (Figure 3D), fail to enter into the myogenic differentiation program, display a 60% reduction in myogenin protein levels (Figure 3E), and hence exhibit low expression levels of muscle proteins required for myofibrillogenesis, like sarcomeric MyHC (Figure 3C, 3F). Summarized, these data indicate a crucial role for cullin E3-ubiquitin ligase activity for entry into the terminal myogenic differentiation program, as crucial muscle transcription factors, like myogenin, are not induced upon myoblast differentiation. Consequently, inhibitor treated cells fail to upregulate muscle specific proteins, like MyHC or alpha-actinin.

Mouse and human satellite cells treated with MLN4924 fail to differentiate

C2C12 cells were originally isolated from dystrophic mouse muscle [27], but have since been widely used as a standard model for muscle cell differentiation and myofibrillogenesis

[28–31]. We wondered whether the findings from this cell line would be reproducible with primary cultures of isolated mouse and human muscle stem cells (satellite cells).

To test this, we freshly isolated muscle stem cells from mouse hind-limbs, and differentiated them in presence or absence of MLN4924. Similar to differentiating C2C12 cells, muscle stem cells did not form myotubes in presence of MLN4924 (Figure 4A), and failed to enter into the terminal myogenic differentiation program, as MyHC expression was found to be reduced, compared to vehicle treated controls (Figure 4B). In resemblance to inhibitor treated C2C12 cells, the reduction in MyHC parallels the inhibitory effect on cullin activity, as seen in a loss of the neddylated form of cullin-1 (Figure 4B, upper panel). In addition, the effect of MLN4924 on muscle cell differentiation is also readily observed in human muscle stem cell-derived myoblasts, which failed to differentiate into myotubes after 3 days in presence of 330nM MLN4924, as demonstrated by the lack of multinucleated myotubes expressing MyHC and myogenin (Figure 4C, 4D).

Cullin inhibition interferes with acetylcholine receptor clustering

We demonstrated that cullin E3-ubiquitin ligase activity is crucial for entry into the terminal myogenic differentiation program and myotube formation. Another important step during skeletal muscle differentiation is the formation of neuromuscular junctions (NMJ). During NMJ formation, acetylcholine receptors (AChR) are densely packed into clusters. This step is initiated by the expression of agrin [32]. *In vitro*, the clustering of AChR can be induced by treating myotubes with neural agrin. We tested if cullin activity is also required for this step in the skeletal muscle differentiation program, by treating differentiated myotubes at day 5 with agrin overnight in presence or absence of MLN4924. While vehicle treated control C2C12 myotubes demonstrated acetylcholine receptor clustering upon agrin stimulation, inhibitor treated control cells showed reduced cluster formation (Figure 5A). To see, whether this effect is statistically significant, we measured several parameters, including myotube length (Figure 5B), the number of nuclei per myotube (Figure 5C), the number of acetylcholine receptor clusters per myotube (Figure 5D), the number of acetylcholine receptor clusters/mm² (Figure 5E), and the acetylcholine receptor cluster length/mm² (Figure 5F). While MLN4924 treatment of differentiated myotubes does not alter myotube length, the number of nuclei per myotube, or the number of acetylcholine receptor clusters per myotube, the cluster density (cluster/mm²) and length (cluster length/mm²) were slightly but significantly reduced. These data point toward another potential function for cullin activity, in the formation of the neuromuscular junction.

The effects of cullin inhibition on terminal muscle differentiation are reversible

MLN4924 is currently undergoing clinical trials as potential approach for the treatment of various cancers, including acute myelogenous leukemia (AML) [14, 33–36]. Drug escalation studies [35] and other clinical trials [33] administer the drug typically either on an intermittent protocol (e.g. on days 1, 4, 8, and 11 of a 2 week protocol) or continuous for up to 5 consecutive days. Analysis of molecular data from mice indicate that MLN4924 disrupts cullin-mediated protein turnover in tumor cells, leading to apoptosis caused by a deregulation of S-phase DNA synthesis [14]. Our data revealed the requirement of cullin

activity for myoblast differentiation, and led us to question whether the effect of MLN4924 on C2C12 myotube development and terminal differentiation is permanent or reversible.

C2C12 cells undergoing differentiation were treated for 5 days with 330nM MLN4924, and subsequently allowed to recover for 5 days in differentiation medium. Cells that were undergoing this treatment were able to differentiate into myotubes (Figure 6A). These cells also upregulated MyHC and desmin, indicating successful entry into the terminal myogenic differentiation program. When we investigated the fusion index, recovered cells were more comparable to C2C12 cells that were differentiated for 5 days, than to C2C12 that were 10 days in differentiation medium (Figure 6B). These data suggest that MLN4924 temporarily interrupts myotube formation and muscle cell differentiation, but that the effects of the drug are reversible *in vitro*. The investigation of MyHC expression levels further substantiated that a recovery of C2C12 differentiation upon removal of MLN4924 is evident. MyHC protein levels in C2C12 cells treated for 5 days with MLN4924 and subsequently left to recover in normal differentiation medium showed comparable MyHC expression to differentiated control cells (Figure 6C, 6D).

MLN4924 mediated blockage of the terminal myogenic differentiation program is partially overcome by removing epigenetic DNA modifications

Recently, a zinc finger and BTB-domain containing protein, ZBTB38 (CIBZ), was shown to be important for the initiation of the myogenic program [37]. ZBTB38 acts as a transcriptional repressor for myogenin expression in proliferative C2C12 myoblasts. Its repressor function can be overcome by treating C2C12 cells with 5-aza-dC (Aza), which is a DNA-methylation inhibitor. DNA-methylation is required for ZBTB38 binding to the myogenin promoter, and repression of myogenin expression [37]. We therefore wondered if additional treatment of C2C12 with Aza may overcome some of the inhibitory effects of MLN4924 on terminal muscle cell differentiation. Indeed, C2C12 cells differentiated in presence of Aza and MLN4924 show elevated expression of alpha-actinin and increased occurrence of alpha-actinin positive cells (Figure 7A–C). Next we asked, whether Aza may indeed contribute to the release of the repression of the myogenin promoter by ZBTB38 in presence of MLN4924.

Quantitative PCR analysis of Aza treated C2C12 cells in presence of MLN4924 show a slight but significant increase of myogenin expression compared to C2C12 cells in presence of MLN4924 alone (Figure 7D). In fact, MLN4924 treated C2C12 show levels of myogenin transcripts similar to those found in proliferating myoblast cultures. The increase in myogenin expression may explain how Aza treatment of differentiating C2C12 in presence of MLN4924 is able to overcome some of the inhibitory effects on muscle differentiation, and result in the increased mRNA and protein levels of alpha-actinin (Figure 7A–C) and MyHC without affecting nedd8 expression (Figure 7E).

The fusion index was also improved by the treatment with Aza (Figure 7F) and the number of myotubes with >4 nuclei was increased compared to MLN treated cells (Figure 7G).

Protein levels of myogenic repressors Bhlhe41 and Id1, but not that of ZBTB38, are mediated through the activity of cullin E3-ligases

In an attempt to determine molecules that might be responsible for the failure to enter into the terminal myogenic differentiation program in cells deprived of cullin activity, we decided to focus on transcriptional factors important for differentiation. Interestingly, several transcriptional repressors of myogenesis are robustly expressed in proliferating myoblasts, and decrease on the protein level within 24 hours after start of differentiation. Among them, ZBTB38 (CIBZ), Bhlhe41 and Id1 represent potential CRL substrates, because they either contain a BTB domain that indicates their interaction with cullin-3 [38, 39], or due to the regulation of their degradation [40], or because of their known interaction with a cullin substrate adaptor [41, 42]. While ZBTB38 protein levels are downregulated during differentiation, its mRNA levels remain unchanged throughout differentiation ([37, 43] and Supplemental Figure S2A). In addition, the differentiation-dependent loss of ZBTB38 on the protein level can be blocked by the proteasome inhibitor MG132, indicating that the ubiquitin-proteasome pathway is actively regulating ZBTB38 protein levels [43]. In contrast, both Id1 and Bhlhe41 are decreased on the transcriptional and on the protein level in differentiating myoblasts [40, 44].

ZBTB38 contains a BTB-domain, whose function poises the protein for interaction with the cullin-3 based E3-ubiquitin ligase [38, 39]. We asked therefore, whether the effect of MLN4924 on myoblast differentiation might be linked to this protein and its regulated degradation by cullin-3. We analyzed ZBTB38 protein levels in differentiating C2C12 cells in presence of MLN4924, and in combination with Aza (Figure 8A). While ZBTB38 protein levels decrease significantly during differentiation, a finding that has been reported previously [37, 43], treatment with MLN4924 was unable to block its active degradation. Intriguingly however, the additional incubation with Aza was consistently able to restore ZBTB38 protein levels comparable to those in proliferative C2C12 cells.

The fact that MLN4924 treatment was unable to prevent the degradation of ZBTB38 indicates that cullin E3-ligases, and more specifically a cullin-3 based E3-ligase, may not be responsible for its poly-ubiquitylation and subsequent degradation. To ultimately rule out the putative involvement of cullin-3 for ZBTB38 degradation we investigated whether both proteins are able to associate in co-immunoprecipitation and pulldown assays. No interaction was found either when probing the interaction with endogenous proteins from differentiating C2C12 cells (Figure 8B), or when using the purified ZBTB38 BTB-domain in combination with C2C12 protein lysates (Figure 8C). A possible mechanism of how ZBTB38 levels might be regulated is found when we investigate changes to the subcellular localization of the protein during skeletal muscle differentiation. We observed a marked shift from a predominantly nuclear localization of ZBTB38 in proliferating C2C12 cells to a predominantly cytoplasmic localization in differentiated C2C12 cells (Figure 8D), a mechanism that has been also observed for the degradation of Id1 [40]. We further investigated if MLN4924 treatment disrupted this shift in subcellular localization and found significant differences between MLN treated and control cells two days after differentiation, indicating that cullin based E3-ligases might indirectly be responsible for the nuclear exclusion of ZBTB38, but not for its direct degradation (Supplemental Figures S2B, S2C).

In contrast to ZBTB38, MLN4924 treatment of differentiating myoblasts increases both Id1 and Bhlhe41 protein but not mRNA levels two days after start of differentiation when compared to untreated control cells, which demonstrate a marked loss of these proteins (Figure 8E, Supplemental Figure S2D). Summarized our data indicate that cullin-based E3-ligases might be responsible for the degradation of myogenic repressors Id1 and Bhlhe41, but not that of ZBTB38.

Discussion

Cullin functions for terminal muscle cell differentiation

The differentiation process from the pluripotent progenitor stem cell, to skeletal muscle stem cells (satellite cells), into functional skeletal muscles, which are anchored and organized into muscle-tendon units, underlies a complex system of biological steps and developmental milestones (Figure 9). Each of those steps is characterized by the change in the genetic program that is derived by the induction of muscle specific transcription factors like MyoD or myogenin (and disappearance of proliferation markers like PCNA [45, 46]) as well as the expression of characteristic muscle proteins, or differentiation ‘milestones’, like myoblast fusion, the formation of the neuromuscular junction or muscle innervation. The premise of our experiments was to delineate the role that cullin-based E3-ligases play for the early steps in the terminal skeletal muscle cell differentiation program. The role for various cullin E3-ligase substrate adaptors during muscle atrophy and various forms of skeletal muscle myopathy is very well investigated. Specifically, the functions of the cullin-1 specific substrate adaptor atrogin-1 (MAFbx, Fbxo32) [10], and more recently through cullin-3 interacting substrate adaptors [11, 47, 48] are well characterized. However, investigations into biological functions of cullin E3-ligases activity during muscle cell differentiation are largely lacking.

By using the C2C12 skeletal muscle cell line, and the small inhibitor MLN4924 that acts downstream of the Nae1 E1-enzyme on cullin activity we were able to tease out the role for this class of ubiquitin ligases for three of the crucial steps during skeletal muscle differentiation: commitment to the terminal myogenic differentiation program, myoblast fusion, and acetylcholine receptor clustering.

Commitment to the terminal myogenic differentiation program—The requirement of cullin activity for entry into the terminal myogenic differentiation program is one of the major findings of our study. Reasoning that cullin-mediated E3-ligase function may be required for the degradation of an inhibitory factor/repressor for myogenic transcription factors we screened for proteins that are known to be degraded by cullin-based ubiquitin ligases, interact with a protein that contains one of the known cullin substrate adaptor domains (e.g. F-box domain, VHL-box domain, BTB/POZ domain or SOCS-domain), or is a protein that itself incorporates a cullin substrate adaptor domain.

A multitude of proteins have been shown to act as repressor for the entry into the myogenic program. Examples include ATBF1-A (ZFHX3) [49], Id1 [50, 51], Teashirt-3 [52], Hey-1 [53], HMGA1 [54], the MBD2-interacting zinc finger protein MIZF [55], Staufin1 [56], JAZF1 [57], Foxk1 [58], Bhlhe41 (DEC2, Sharp1) [44] or ZBTB38 (CIBZ) [37, 43]. Little

is known about any association of these proteins to cullin-linked protein degradation. Only Bhlhe41 was shown to interact with Fbxw11 (beta-TRCP2) [41], a known substrate adaptor for cullin-1 [42], thereby indicating that this basic helix-loop-helix transcription factor may be degraded in a cullin-dependent way. Although, Id1 and ZBTB38 have been shown to be degraded through the ubiquitin proteasome system [40, 43], it remained unclear if cullin E3-ligases play a role in their degradation. However, the zinc finger protein ZBTB38 contains a BTB-domain, predisposing the protein to interact with cullin-3 [38, 39]. Hence, we decided to focus on these three repressor proteins, and investigated if loss of their regulated degradation in absence of CRL activity could be responsible for the lack of terminal muscle cell differentiation.

Our data show that ZBTB38 protein degradation is not regulated through a cullin E3-ubiquitin ligase dependent mechanism, and that the protein does not associate with cullin-3. Thereby, our data add for the first time ZBTB38 to the short list of BTB-domain proteins that were recently shown to not bind to cullin-3 [59, 60].

We also investigated Bhlhe41 and Id1 protein levels, which are found decreased during differentiation. Treatment with MLN4924 led to their accumulation, with protein levels similar or in excess to the undifferentiated state of C2C12 cells, thus indicating that both myogenic repressors are potential targets for cullin-mediated protein degradation.

An unexpected finding of our experiments to reverse MLN4924 induced blockage of terminal skeletal muscle differentiation was that the addition of 10 μ M 5-aza-dC (Aza) to the medium enhanced ZBTB38 protein levels. Aza has been shown to induce UCHL1, a de-ubiquitylating enzyme [61], thereby promoting stability of poly-ubiquitylated substrate proteins. This mechanism might be responsible for the observed increase in ZBTB38 protein levels. Intriguingly, UCHL1 protein levels are decreased during muscle differentiation [62], but can be elevated in atrophic muscles [63, 64]. UCHL1 was also required to maintain the structure of the NMJ, however not in the post-synaptic muscle, but the pre-synaptic nerve [65].

Myoblast fusion—Myoblast fusion is another important step during skeletal muscle differentiation. The fusion process has been shown to involve cell-migration, cell-recognition and -adhesion, cytoskeletal remodeling, fusion related activation of signaling pathways as well as assembly and activation of proteins that make out the ‘fusion machinery’, which leads to membrane remodeling and ultimately fusion of the differentiating myoblasts (for a review see: [66, 67]). We noted in our timed inhibitor experiment (Figures 1E–G) and in the experiments involving 5-aza-dC (Aza; Figures 7A–C, 7F) a lack of myoblast fusion.

Specifically, addition of MLN4924 after 3 days of differentiation still lead to a pronounced defect in the fusion index (Figure 1F), when compared to control cells. That is despite the fact that expression of many transcription factors necessary for terminal muscle differentiation (e.g. myogenin [68]), as well as proteins that are involved in the fusion of myoblasts (e.g. myomaker (TMEM8C) [69]) already peak at this stage during myotube development, and hence should not be affected by inhibition of cullin-RING ligase

functions. Moreover, in our experiments involving 5-aza-dC (Aza) we also noticed a lack of expected myoblast fusion. This is mostly based on the discrepancy between alpha-actinin positive cells after additional treatment with Aza (Figure 7C), which lead to a more pronounced increase, compared to the measured increase in the fusion index (Figure 7F). This discrepancy might be attributed to a defect in myotube fusion that is not overcome by Aza treatment.

Acetylcholine receptor (AChR) clustering—Neuromuscular junction (NMJ) development and formation relies on acetylcholine receptor clustering. *In vivo*, this developmental step is dependent on signaling molecules coming from both presynaptic (i.e. neural agrin) and postsynaptic (i.e. MusK, Rapsyn) elements [70]. Recently, data revealed that neddylation is involved in synapse structure and maintenance in hippocampal neurons [71]. However, the effect of the loss of Cullin-RING ligase activity on the post-synaptic element of neuromuscular junction has never been investigated. *In vitro*, AChR clustering can be induced by treating myotubes with neural agrin [72]. Our data indicate that agrin induced-AChR clustering is impaired in absence of cullin activity. Interestingly, Rpy-1, the ortholog of Rapsyn in *C. elegans*, can be degraded by a cullin-RING ligase [73], suggesting unexplored functions for cullin-RING ligases (CRL) and their substrates in the formation of NMJ. Our data indicate that a defective ubiquitylation activity through CRL inhibition might either interfere with the abundance of proteins that are important for neuromuscular junction development, or with cytoskeletal remodeling that has been shown to be important for the agrin-induced AChR clustering process [74–79]. Indeed, several members of the cullin protein family associate with, and are capable of remodeling actin and tubulin filaments in non-muscle cells [80–84]. The biological function of these CRL at the cytoskeleton may also extend to myoblasts, as we find cullin-3 associated with the tubulin cytoskeleton in skeletal muscle myoblasts (Supplemental Figure S3). Further investigation will be needed to understand the importance of the turnover regulation of proteins involved in synaptogenesis and NMJ formation [70].

Clinical implications for cullin inhibition

Unexpectedly, this study also brings up a potential therapeutic concern for patients treated with MLN4924. Cullin based E3-ubiquitin ligases play a major role for cell survival and signalling. Indeed, most of the biological roles for cullin based E3-ubiquitin ligases have been assigned to fundamental functions like their critical involvement in the cell-cycle, apoptosis, cell migration or cell proliferation. These attributes have made cullin proteins an attractive anti-cancer target [14, 17, 85–87]. While CRL functions can be disrupted in many ways, MLN4924 (Pevonedistat) has emerged as one of the first compounds to be tested in phase I clinical trials, as it is effective against a variety of cancers and is able to inhibit the entire family of cullin-based ubiquitin ligases [85]. Although the concentrations and administration regimens used for tests in mice and in clinical trials vary, dosages of up to 150mg/kg have been reported [34], which equals to a 'global' MLN4924 concentration of approximately 350µM for the average mouse with a weight of 40g, or a human with a weight of 69kg. Data from our dose-response curve (Figure 2B) indicated that the IC₅₀ of MLN4924 on the C2C12 myotube fusion index is approximately 100nM, more than 3 magnitudes lower than the approximate concentration achieved *in vivo*. Although our IC₅₀

value on the fusion index of ~100nm is 25 times higher than the reported IC50 of NAE1 itself, it is at least 10 times lower than MLN4924 inhibition of NAE1 related enzymes UAE, SAE, UBA6 or ATG7 [14]. The measured IC50 of MLN4924 on the fusion index indicates that the observed effects are likely due to inhibition of NAE1, and subsequent suppression of cullin E3-ligase activity, and not off-target effects on NAE1-related enzymes. This finding is also supported by our siRNA experiment that specifically inhibits cullin activation through knockdown of nedd8 (Figures 2D–E).

Numerous cancer patients develop a pathological muscle loss, a symptom associated with the cachexia syndrome. Cachexia is estimated to be responsible for the death of 20% of patients with cancer [22]. A recent study revealed that muscle regeneration and satellite cell differentiation are affected in cachectic mice and that defective myogenesis may participate to the muscle wasting observed in patients [23]. For the first time we show that MLN4924, a drug used in clinical studies for cancer therapy, may interfere with the terminal muscle cell differentiation *in vitro*. If validated *in vivo*, a synergistic effect of MLN4924 over the myoblast differentiation program combined with the satellite cells defect observed in cachectic patients [22, 23] would be detrimental. It seems essential to closely monitor skeletal muscles of patients treated with MLN4924 in future studies.

Material and Methods

C2C12 and primary myoblast cell culture and reagents

C2C12 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Corning Life Sciences, Tewksbury, MA) containing 4.5g/l glucose, supplemented with 15% fetal bovine serum (FBS, Gemini Bio-Products, Sacramento, CA) and penicillin/streptomycin (Cellgro). Cells were maintained at 37°C in a saturated humidity atmosphere containing 5% CO₂. Differentiation of C2C12 myoblasts was triggered when cells reached 70% of confluency, by replacing FBS with 2% horse serum (Lonza BioWhittaker, Basel, Switzerland). The fusion index was calculated as the mean number of nuclei per myotube at day 5 of differentiation. Myotubes were defined as sarcomeric myosin-heavy chain or alpha-actinin positive cells containing at least 2 nuclei.

Mouse primary myoblasts were obtained by dissection of hind limb muscles from 1 month-old mice. Muscles were digested in Collagenase B-Dispase II (Roche, USA) solution for 30 minutes at 37°C. Cell suspension was filtered through a 75µm cell strainer, pelleted via centrifugation, resuspended in Ham's complete medium (Ham's F-10 media, Corning Life Sciences, Tewksbury, MA), 20% FBS, 2% penicillin-streptomycin (Cellgro) and bFGF (5ng/mL; Invitrogen, Carlsbad, CA) and pre-plated on uncoated dish for 2 hours at 37°C with 5% CO₂. Supernatant was collected and plated on 0.2% gelatin (Sigma, Saint-Louis, MO) coated dish and cells were incubated at 37°C with 5% CO₂. Ham's complete medium was refreshed every 2 days. Differentiation of cells was achieved with 2% horse serum (Lonza BioWhittaker, Basel, Switzerland).

MLN4924 compound was purchased from LifeSensors, Inc. (Malvern, PA), redissolved in DMSO and stock solution was stored at a concentration of 1mM at –20°C. 5-aza-dC (Aza) was purchased from Fisher Scientific and re-dissolved in DMSO. Working solutions were

prepared by dilution of stock solution into culture media. Media with inhibitors was refreshed every 48 hours. Control cells were treated with a corresponding concentration of DMSO (Sigma-Aldrich).

90KDa recombinant rat agrin compound was purchased from R&D Systems (Minneapolis, MN), reconstituted in sterile PBS containing 0.1% BSA. Acetylcholine receptor clustering was induced by overnight incubation with 5ng/mL recombinant rat agrin.

siRNA

Proliferating C2C12 cells were transfected with siRNA directed against nedd8 (ON-TARGETplus mouse nedd8 (18002) individual siRNA; GE Healthcare Dharmacon) or scrambled control (ON-TARGETplus non-targeting siRNA #1; GE Healthcare Dharmacon) using DharmaFECT 1 transfection reagent (GE Healthcare Dharmacon) according to the manufacturers instructions. 24 hours after transfection, cells were changed into differentiation medium, and allowed to proliferate for 3 or 5 days before analysis.

Isolation and culture of human myoblasts

Human satellite cells were enzymatically isolated from semitendinosus and gracilis muscle biopsies obtained from typically developing children (n= 8 patients, 16.4±1.6 years old). The University of California San Diego Human Research Protection Program provided ethical approval, and appropriate assents/consents were obtained from children and their parents. Satellite cells were isolated by enzymatic procedures as previously described [88]. Briefly, satellite cells were isolated by sequential digestion in a Collagenase B – Dispase II solution (Roche) at 37°C, and resuspended in FACS buffer before being sorted by flow cytometry (fluorescence-activated cell sorting or FACS). Satellite cells were sorted from other cell populations using specific cell surface markers and were defined as a population of CD31–/CD45–/CD56+/ITGA7+ mono-nucleated cells, as previously published [89]. Satellite cells-derived myoblasts were expanded *in vitro* in Ham's F-10 medium (Corning Life Sciences, Tewksbury, MA), supplemented with 20% FBS, 2% penicillin-streptomycin (Cellgro) and bFGF (5ng/mL; Invitrogen, Carlsbad, CA) on 0.2% (porcine) gelatin-coated dishes. To stimulate fusion and myotubes formation, the medium was switched to a low-serum medium containing DMEM (1g/L glucose) and 2% Horse Serum (HS) (Lonza BioWhittaker, Basel, Switzerland) when myoblasts reached 60–70% confluence.

Cloning and protein purification

The murine version of the ZBTB38 BTB-domain (accession number: **NM_175537**) was subcloned in frame to the GST-C1 vector [90] using murine skeletal muscle cDNA as a template and standard PCR conditions with the following oligonucleotides ZBTB38-BTB.fwd: CCGCTCGAGCCACCATGACAGTCATGTCCCTCTCC; ZBTB38-BTB.rev: GGAATTCGAGGACCTGGGGAATTTGAG. The construct was subsequently verified for correct integration by sequencing.

Expression of the GST-tagged BTB-domain of ZBTB38, or GST alone was done by transforming BL21 cells (C601003; Invitrogen; ThermoFisher Scientific), and growing them in 400ml of LB-medium supplemented with 50µg/ml carbenicillin on an orbital shaker at

37°C to an OD600 of >600. Expression of the GST-fusion protein or GST alone was induced by addition of 0.2mM IPTG (Isopropyl b-D-1-thiogalactopyranoside), and performed for approximately 12 hours at 18°C. Cells were pelleted, and lysed into 40 ml ice cold lysis buffer (150mM NaCl, 10mM Tris-HCl pH 8, 1% Triton X100), followed by sonication for 1 min at 4°C, 70% output (Vibracell, Sonics & Materials Inc., Newtown, CT). Insoluble cell debris was removed by centrifugation (45 min at 11,000 rpm, 4°C; Sorvall) and the supernatant was incubated with 400 µl glutathione-sepharose beads (bioPLUS fine research chemicals) for 2 hours at 4°C with agitation. After washing of beads with ice cold PBS for three times, bound protein was eluted with GST-elution buffer (150mM NaCl, 50mM Tris-HCl pH 7.4, 150mM reduced glutathione) and dialyzed over night at 4°C against dialysis buffer (20mM HEPES-KOH pH7.4, 10mM MgSO₄, 0.1mM CaCl₂).

Protein interaction assays

To test for interaction of proteins we employed either GST-pulldown assays as described previously [90], or co-immunoprecipitation (CoIP) assays.

For CoIP and pulldown-assays, confluent cultures of differentiating C2C12 cultures (2 days after differentiation start) were lysed into ice-cold lysis buffer (150mM NaCl, Tris-HCl pH 8, 1mM DTT, 1x Complete Protease Inhibitor EDTA-free (Roche), 1x PhosSTOP (Roche), 0.2% NP-40). Insoluble cell debris was removed by centrifugation at 14,000 rpm at 4°C for 10 min. For GST-pulldown assays, cell lysates were incubated with 2µg of either GST-ZBTB38 (BTB-domain) or GST alone for 2 hours at 4°C on a rotating shaker, followed by addition of 20 µl glutathione-sepharose beads (bioPLUS fine research chemicals) and additional incubation for 1 hour. Beads were washed three times with ice-cold PBS, and bound proteins were analyzed by SDS-page following immunoblot analysis. For CoIP, cell lysates were pre-cleared using G-protein linked magnetic beads (Dynabeads; ThermoFisher Scientific) for 1 hour at 4°C on a rotating shaker. After pre-clearing, lysates were incubated with 1µg of primary antibody or control serum for 2 hours at 4°C. After addition of G-protein linked magnetic beads (Dynabeads), lysates were incubated on a rotating shaker at 4°C for an additional hour, centrifuged, and beads were washed three times with ice-cold PBS. After the last wash, PBS solution was removed, and bound proteins were eluted off the beads using SDS sample buffer. Samples were analyzed using SDS-page, followed by immunoblot analysis.

Extraction of total RNA, RT-PCR and RT-qPCR analysis

Cells were washed with PBS, then lysed using TRIzol reagent (ThermoFisher Scientific). RNA was extracted according to the manufacturers instructions. Purity of RNA was assessed by a ratio of absorbance at 260nm and 230nm >1.7. 200ng of RNA was used for reverse transcriptase reaction using the Maxima First Strand cDNA Synthesis kit (Fermentas; ThermoFisher Scientific) and random hexamers.

Oligonucleotides optimized for qPCR of murine myogenin (myogenin.fwd: CTACAGGCCTTGCTCAGCTC; myogenin.rev: AGATTGTGGGCGTCTGTAG), GAPDH (GAPDH.fwd: GCTCATGACCACAGTCCATG; GAPDH.rev: GAAGGCCATGCCAGTGAGC), cyclophilin B (cycloB.fwd:

GATGGCACAGGAGGAAAGAG; cycloB.rev: AACTTTGCCGAAAACCACAT), nedd8 (nedd8.fwd: TCTACAGTGGCAAGCAAATGA; nedd8.rev: TTTCTTCACTGCCCCAAGACC), Id1 (Id1.fwd: GCGAGATCAGTGCCTTGG; Id1.rev: CTCCTGAAGGGCTGGAGTC) and ZBTB38 (ZBTB38.fwd: AGGCTGGCGTGTCTGAG; ZBTB38.rev: CACTGTGAAAGTCGTCCTTGAG) were used in reactions employing the PerfeCTa SYBR green real-time PCR mix (Quanta BioSciences; Beverly, MA) and a CFX96 thermocycler (BioRad; Hercules, CA). Samples were normalized either to GAPDH or cyclophilin B. If not noted otherwise, three biological samples were analyzed per sample group.

Immunofluorescence microscopy

Cells were rinsed one time with PBS, fixed for 15 minutes with 4% paraformaldehyde and rinsed 3 times with PBS. For labeling of mitochondria, cells were incubated with fluorescently labeled MitoTracker (ThermoFisher Scientific) according to the manufacturers instructions before fixation. Cells were then permeabilized for 10 minutes in 1xPBS supplemented with 0.2% Triton X-100 (Sigma Aldrich; St. Louis, MO), washed 3 times with PBS and incubated in blocking solution (Gold Buffer [GB, 150mM NaCl, 20mM Tris pH7.4] supplemented with 1% BSA) for 1 hour at room temperature before incubation with primary antibodies against pan-sarcomeric myosin heavy chain (clone 1025, DSHB), alpha-actinin (clone EA-53, VWR), Desmin (Santa Cruz Biotechnology; Dallas, TX), ZBTB38 (R&D Systems; Minneapolis, MN), myogenin (clone F5D), beta-tubulin (clone E7, DSHB) or MYH7 (clone BA-D5, DSHB) diluted in blocking solution. Primary antibodies were either incubated for 2 hours at room temperature, or overnight at 4°C. Following incubation, cells were washed three times for 5 minutes with PBS, and incubated with secondary antibodies (all from Jackson ImmunoResearch Laboratories Inc.; West Grove, PA) diluted into blocking solution for 1 hour at room temperature. Secondary antibody mixtures also contained DAPI (4', 6' diamidino-2-phenylindol) and/or fluorescently linked alpha-bungarotoxin (BTX; Molecular Probes, ThermoFisher Scientific), Alexa Fluor 488 conjugate of wheat germ agglutinin (WGA; ThermoFisher Scientific) or fluorescently labeled phalloidin (Molecular Probes; ThermoFisher Scientific) when appropriate. After washing three times with PBS for 5 minutes, cells were mounted using fluorescent mounting medium (Dako; Carpinteria, CA). Microscopy was performed using an Olympus FV1000 confocal microscope using either the 20x air objective, the 40x or 63x oil immersion objective, zoom rates between 1 and 3, and in sequential scanning mode.

Evaluation of fluorescent cytoplasmic versus nuclear ZBTB38 localization ratios was done as described previously [71], using ImageJ (1.48v) [91] and Excel.

Staining and quantification of acetylcholine receptors (AChRs) in C2C12 myotubes

After 5 days of differentiation, myotubes were treated with MLN4924 compound or DMSO for one day then incubated with recombinant rat agrin overnight at 37°C in 5% CO₂. Treated cells with recombinant rat agrin were fixed in PFA 4% for 10 minutes. Quantification of AChR expressed at the myotubes surface was determined by incubating fixed cells with FITC-conjugated alpha-bungarotoxin (Molecular Probes, ThermoFisher) for one hour at room temperature. Confocal microscopy was performed using a Zeiss Axioplan 2 upright

confocal microscope (Carl Zeiss Inc., Thornwood, NY). Area, number and size of AChR were assessed using ImageJ (1.48v) software [91].

Western blot analysis

Cells were washed in PBS and put in lysis buffer (150mM NaCl, 50mM Tris-HCl pH8, 0,1% Triton-100, 1x Complete EDTA-free protease inhibitor (Roche; Indianapolis, IN), 1x PhosStop phosphatase inhibitor (Roche; Indianapolis, IN)) for 20 minutes on ice. Lysates were sonicated and spun for 10 minutes at 10000g. After quantification of protein concentration using Pierce BCA Protein Assay Kit (ThermoFisher Scientific; Waltham, MA), 5 to 15µg of clarified lysates were separated by SDS-PAGE. Transfer was performed on nitrocellulose membranes (BioRad). Membranes were incubated with blocking solution (TBS-Tween containing 5% BSA) for 1 hour at room temperature, then incubated with antibodies against cullin1 (Sigma Aldrich; St. Louis, MO), cullin3 (Sigma Aldrich; St. Louis, MO, or gift from J. Singer), nedd8 (Cell Signaling; Danvers, MA), pan-sarcomeric myosin heavy chain (clone 1025, DSHB), myogenin (clone F5D, from DSHB and Abcam), ZBTB38 (R&D Systems; Minneapolis, MN), Bhlhe41 (ARP33575; AVIVA Systems Biology, San Diego, CA), Id1 (sc-133104; Santa Cruz Biotechnologies), or GAPDH (Santa Cruz Biotechnologies) in blocking solution overnight at 4°C. After washing, secondary HRP-linked antibodies (DAKO, Cell Signaling) were applied for 1 hour at room temperature. After washing, antibody-bound proteins were visualized on X-ray films. Quantification of band intensities was performed using ImageJ software (1.48v) [91].

Statistical analysis

Significance was assessed using the two-tailed student's t-test. Data are expressed as mean $\pm$ standard error of the mean, and differences were considered statistically significant if $p < 0.05$.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding for this project was provided by an NIH-NHLBI K99/R00 and R01 grant to SL (HL107744, HL128457), and supported by a Philippe Foundation grant to JB, and a UC San Diego Ledell Family Undergraduate Research Scholarship to PS. We would like to thank the UC San Diego Microscopy Core and Jennifer Santini, who are supported by an NIH-NINDS P30 grant (NS047101). We acknowledge Dr. Henry G. Chambers, MD (Children's Hospital and Health Center, San Diego, CA) for providing the human muscle biopsies, and Dr. Margie A. Mathewson, PhD (Department of Orthopedic Surgery, UC San Diego, La Jolla, CA) for her expertise in FACS sorting the human satellite cells. We express our gratitude to Jeffrey Singer (Portland State University) for insightful discussions, and provision of the cullin-3 antibody. The pan-sarcomeric myosin heavy chain antibody (clone 1025), slow myosin heavy chain (MYH7, clone BA-D5), beta-tubulin (clone E7) and myogenin antibody (clone F5D) were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.

Abbreviations

AChR	acetylcholine receptor
Aza	5-aza-dC

BTX	alpha-bungarotoxin
BTB	Bric-a-Brac, Tramtrack, Broad-complex
CRL	cullin-RING ligase
CTL	control
DAPI	4', 6' diamidino-2-phenylindol
Diff	differentiation
FT	flow-through
IC50	half maximal inhibitory concentration
IP	immunoprecipitate
MyHC	myosin heavy chain
NAE1	NEDD8 Activating Enzyme E1 Subunit 1
NMJ	neuromuscular junction
Pro	proliferation
siRNA	small interfering RNA
UCHL1	Ubiquitin C-Terminal Hydrolase L1
WGA	wheat germ agglutinin

Bibliography

1. Blaauw B, Schiaffino S, Reggiani C. Mechanisms modulating skeletal muscle phenotype. *Compr Physiol*. 2013; 3:1645–87. [PubMed: 24265241]
2. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. *Int J Biochem Cell Biol*. 2013; 45:2121–9. [PubMed: 23665154]
3. Blondelle, J., Lange, S. Cardiac Cytoarchitecture: How to Maintain a Working Heart Waste—Disposal and Recycling in Cardiomyocytes. In: Ehler, E., editor. *Cardiac Cytoarchitecture*. 1. Springer; 2015. p. 245-309.
4. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. *Nature*. 2003; 426:895–9. [PubMed: 14685250]
5. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. *Dis Model Mech*. 2013; 6:25–39. [PubMed: 23268536]
6. Bosu DR, Kipreos ET. Cullin-RING ubiquitin ligases: global regulation and activation cycles. *Cell Div*. 2008; 3:7. [PubMed: 18282298]
7. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. *Nat Rev Mol Cell Biol*. 2005; 6:9–20. [PubMed: 15688063]
8. Zhou W, Wei W, Sun Y. Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases. *Cell Res*. 2013; 23:599–619. [PubMed: 23528706]
9. Kamitani T, Kito K, Nguyen HP, Yeh ET. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. *J Biol Chem*. 1997; 272:28557–62. [PubMed: 9353319]
10. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science*. 2001; 294:1704–8. [PubMed: 11679633]

11. Gupta VA, Beggs AH. Kelch proteins: emerging roles in skeletal muscle development and diseases. *Skelet Muscle*. 2014; 4:11. [PubMed: 24959344]
12. Lee J, Zhou P. Cullins and cancer. *Genes Cancer*. 2010; 1:690–9. [PubMed: 21127736]
13. Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. *Trends in biochemical sciences*. 2009; 34:562–70. [PubMed: 19818632]
14. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature*. 2009; 458:732–6. [PubMed: 19360080]
15. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. *EMBO J*. 2000; 19:2069–81. [PubMed: 10790373]
16. Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. *Genes & development*. 1999; 13:2375–87. [PubMed: 10500095]
17. Zhao Y, Sun Y. Cullin-RING Ligases as attractive anti-cancer targets. *Current pharmaceutical design*. 2013; 19:3215–25. [PubMed: 23151137]
18. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, et al. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. *Clin Cancer Res*. 2016; 22:34–43. [PubMed: 26561559]
19. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, et al. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2016; 22:847–57. [PubMed: 26423795]
20. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. *Nat Rev Cancer*. 2014; 14:754–62. [PubMed: 25291291]
21. Warren S. The immediate causes of death in cancer. *The American Journal of the Medical Sciences*. 1932; 184:610–5.
22. Skipworth RJ, Stewart GD, Dejong CH, Preston T, Fearon KC. Pathophysiology of cancer cachexia: much more than host-tumour interaction? *Clin Nutr*. 2007; 26:667–76. [PubMed: 17507116]
23. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. *J Clin Invest*. 2013; 123:4821–35. [PubMed: 24084740]
24. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *The Lancet Oncology*. 2008; 9:629–35. [PubMed: 18539529]
25. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *The Lancet Oncology*. 2011; 12:489–95. [PubMed: 21296615]
26. Hakenjos JP, Richter R, Dohmann EM, Katsiarimpa A, Isono E, Schwechheimer C. MLN4924 is an efficient inhibitor of NEDD8 conjugation in plants. *Plant Physiol*. 2011; 156:527–36. [PubMed: 21527421]
27. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature*. 1977; 270:725–7. [PubMed: 563524]
28. DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F, et al. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. *PLoS One*. 2010; 5:e13039. [PubMed: 20885963]
29. Hildyard JC, Wells DJ. Identification and validation of quantitative PCR reference genes suitable for normalizing expression in normal and dystrophic cell culture models of myogenesis. *PLoS currents*. 2014;6.
30. Hinterberger TJ, Barald KF. Fusion between myoblasts and adult muscle fibers promotes remodeling of fibers into myotubes in vitro. *Development*. 1990; 109:139–47. [PubMed: 2209461]

31. Silberstein L, Webster SG, Travis M, Blau HM. Developmental progression of myosin gene expression in cultured muscle cells. *Cell*. 1986; 46:1075–81. [PubMed: 3530499]
32. Smith MA, Yao YM, Reist NE, Magill C, Wallace BG, McMahan UJ. Identification of agrin in electric organ extracts and localization of agrin-like molecules in muscle and central nervous system. *J Exp Biol*. 1987; 132:223–30. [PubMed: 2828510]
33. clinicaltrials.gov.
34. Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, et al. Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. *Cancer Cell*. 2012; 21:388–401. [PubMed: 22439935]
35. Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. *Br J Haematol*. 2015; 169:534–43. [PubMed: 25733005]
36. Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. *Expert Opin Ther Targets*. 2011; 15:253–64. [PubMed: 21219242]
37. Oikawa Y, Omori R, Nishii T, Ishida Y, Kawaichi M, Matsuda E. The methyl-CpG-binding protein CIBZ suppresses myogenic differentiation by directly inhibiting myogenin expression. *Cell Res*. 2011; 21:1578–90. [PubMed: 21625269]
38. Geyer R, Wee S, Anderson S, Yates J, Wolf DA. BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. *Molecular cell*. 2003; 12:783–90. [PubMed: 14527422]
39. Xu L, Wei Y, Reboul J, Vaglio P, Shin TH, Vidal M, et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. *Nature*. 2003; 425:316–21. [PubMed: 13679922]
40. Sun L, Trausch-Azar JS, Ciechanover A, Schwartz AL. Ubiquitin-proteasome-mediated degradation, intracellular localization, and protein synthesis of MyoD and Id1 during muscle differentiation. *J Biol Chem*. 2005; 280:26448–56. [PubMed: 15888449]
41. Wallach T, Schellenberg K, Maier B, Kalathur RK, Porras P, Wanker EE, et al. Dynamic circadian protein-protein interaction networks predict temporal organization of cellular functions. *PLoS genetics*. 2013; 9:e1003398. [PubMed: 23555304]
42. Suzuki H, Chiba T, Kobayashi M, Takeuchi M, Suzuki T, Ichiyama A, et al. IkappaBalpha ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, betaTrCP1 and betaTrCP2. *Biochemical and biophysical research communications*. 1999; 256:127–32. [PubMed: 10066435]
43. Oikawa Y, Matsuda E, Nishii T, Ishida Y, Kawaichi M. Down-regulation of CIBZ, a novel substrate of caspase-3, induces apoptosis. *J Biol Chem*. 2008; 283:14242–7. [PubMed: 18375381]
44. Azmi S, Ozog A, Taneja R. Sharp-1/DEC2 inhibits skeletal muscle differentiation through repression of myogenic transcription factors. *J Biol Chem*. 2004; 279:52643–52. [PubMed: 15448136]
45. Yablonka-Reuveni Z. The skeletal muscle satellite cell: still young and fascinating at 50. *The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society*. 2011; 59:1041–59. [PubMed: 22147605]
46. Deponti D, Francois S, Baesso S, Sciorati C, Innocenzi A, Broccoli V, et al. Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation. *The Journal of cell biology*. 2007; 179:305–19. [PubMed: 17954612]
47. Wilson KJ, Qadota H, Mains PE, Benian GM. UNC-89 (obscurin) binds to MEL-26, a BTB-domain protein, and affects the function of MEI-1 (katanin) in striated muscle of *Caenorhabditis elegans*. *Molecular biology of the cell*. 2012; 23:2623–34. [PubMed: 22621901]
48. Lange S, Perera S, Teh P, Chen J. Obscurin and KCTD6 regulate cullin-dependent small ankyrin-1 (sAnk1.5) protein turnover. *Molecular biology of the cell*. 2012; 23:2490–504. [PubMed: 22573887]
49. Berry FB, Miura Y, Mihara K, Kaspar P, Sakata N, Hashimoto-Tamaoki T, et al. Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple

- homeodomain zinc finger transcription factor ATBF1. *J Biol Chem.* 2001; 276:25057–65. [PubMed: 11312261]
50. Qiu H, Liu N, Luo L, Zhong J, Tang Z, Kang K, et al. MicroRNA-17-92 regulates myoblast proliferation and differentiation by targeting the ENH1/Id1 signaling axis. *Cell death and differentiation.* 2016; 23:1658–69. [PubMed: 27315298]
51. Langlands K, Yin X, Anand G, Prochownik EV. Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. *J Biol Chem.* 1997; 272:19785–93. [PubMed: 9242638]
52. Faralli H, Martin E, Core N, Liu QC, Filippi P, Dilworth FJ, et al. Teashirt-3, a novel regulator of muscle differentiation, associates with BRG1-associated factor 57 (BAF57) to inhibit myogenin gene expression. *J Biol Chem.* 2011; 286:23498–510. [PubMed: 21543328]
53. Buas MF, Kabak S, Kadesch T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. *J Biol Chem.* 2010; 285:1249–58. [PubMed: 19917614]
54. Brocher J, Vogel B, Hock R. HMGA1 down-regulation is crucial for chromatin composition and a gene expression profile permitting myogenic differentiation. *BMC cell biology.* 2010; 11:64. [PubMed: 20701767]
55. Sekimata M, Homma Y. Regulation of Rb gene expression by an MBD2-interacting zinc finger protein MIZF during myogenic differentiation. *Biochemical and biophysical research communications.* 2004; 325:653–9. [PubMed: 15541338]
56. Ravel-Chapuis A, Crawford TE, Blais-Crepeau ML, Belanger G, Richer CT, Jasmin BJ. The RNA-binding protein Staufen1 impairs myogenic differentiation via a c-myc-dependent mechanism. *Molecular biology of the cell.* 2014; 25:3765–78. [PubMed: 25208565]
57. Yuasa K, Aoki N, Hijikata T. JAZF1 promotes proliferation of C2C12 cells, but retards their myogenic differentiation through transcriptional repression of MEF2C and MRF4-Implications for the role of Jazf1 variants in oncogenesis and type 2 diabetes. *Experimental cell research.* 2015; 336:287–97. [PubMed: 26101156]
58. Shi X, Wallis AM, Gerard RD, Voelker KA, Grange RW, DePinho RA, et al. Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2. *Journal of cell science.* 2012; 125:5329–37. [PubMed: 22956541]
59. Smaldone G, Pirone L, Balasco N, Di Gaetano S, Pedone EM, Vitagliano L. Cullin 3 Recognition Is Not a Universal Property among KCTD Proteins. *PLoS One.* 2015; 10:e0126808. [PubMed: 25974686]
60. Ji AX, Chu A, Nielsen TK, Benlekber S, Rubinstein JL, Prive GG. Structural Insights into KCTD Protein Assembly and Cullin3 Recognition. *Journal of molecular biology.* 2016; 428:92–107. [PubMed: 26334369]
61. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. *International journal of cancer.* 2006; 119:1338–44. [PubMed: 16642472]
62. Gonnet F, Bouazza B, Millot GA, Ziaei S, Garcia L, Butler-Browne GS, et al. Proteome analysis of differentiating human myoblasts by dialysis-assisted two-dimensional gel electrophoresis (DAGE). *Proteomics.* 2008; 8:264–78. [PubMed: 18203276]
63. Gomes AV, Waddell DS, Siu R, Stein M, Dewey S, Furlow JD, et al. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology.* 2012; 26:2986–99. [PubMed: 22508689]
64. Powis RA, Mutsaers CA, Wishart TM, Hunter G, Wirth B, Gillingwater TH. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target. *Neuropathology and applied neurobiology.* 2014; 40:873–87. [PubMed: 25041530]
65. Chen F, Sugiura Y, Myers KG, Liu Y, Lin W. Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. *Proceedings of the National Academy of Sciences of the United States of America.* 2010; 107:1636–41. [PubMed: 20080621]
66. Abmayr SM, Pavlath GK. Myoblast fusion: lessons from flies and mice. *Development.* 2012; 139:641–56. [PubMed: 22274696]

67. Rochlin K, Yu S, Roy S, Baylies MK. Myoblast fusion: when it takes more to make one. *Developmental biology*. 2010; 341:66–83. [PubMed: 19932206]
68. Andres V, Walsh K. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. *The Journal of cell biology*. 1996; 132:657–66. [PubMed: 8647896]
69. Millay DP, O'Rourke JR, Sutherland LB, Bezprozvannaya S, Shelton JM, Bassel-Duby R, et al. Myomaker is a membrane activator of myoblast fusion and muscle formation. *Nature*. 2013; 499:301–5. [PubMed: 23868259]
70. Tintignac LA, Brenner HR, Ruegg MA. Mechanisms Regulating Neuromuscular Junction Development and Function and Causes of Muscle Wasting. *Physiological reviews*. 2015; 95:809–52. [PubMed: 26109340]
71. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:12564–9. [PubMed: 20538976]
72. Godfrey EW, Nitkin RM, Wallace BG, Rubin LL, McMahan UJ. Components of Torpedo electric organ and muscle that cause aggregation of acetylcholine receptors on cultured muscle cells. *The Journal of cell biology*. 1984; 99:615–27. [PubMed: 6746740]
73. Nam S, Min K, Hwang H, Lee HO, Lee JH, Yoon J, et al. Control of rapsyn stability by the CUL-3-containing E3 ligase complex. *J Biol Chem*. 2009; 284:8195–206. [PubMed: 19158078]
74. Chen Y, Ip FC, Shi L, Zhang Z, Tang H, Ng YP, et al. Coronin 6 regulates acetylcholine receptor clustering through modulating receptor anchorage to actin cytoskeleton. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2014; 34:2413–21. [PubMed: 24523531]
75. Luisandl S, Woller B, Schlauf M, Schmid JA, Herbst R. Endosomal trafficking of the receptor tyrosine kinase MuSK proceeds via clathrin-dependent pathways, Arf6 and actin. *The FEBS journal*. 2013; 280:3281–97. [PubMed: 23621612]
76. Madhavan R, Gong ZL, Ma JJ, Chan AW, Peng HB. The function of cortactin in the clustering of acetylcholine receptors at the vertebrate neuromuscular junction. *PLoS One*. 2009; 4:e8478. [PubMed: 20041195]
77. Dai Z, Luo X, Xie H, Peng HB. The actin-driven movement and formation of acetylcholine receptor clusters. *The Journal of cell biology*. 2000; 150:1321–34. [PubMed: 10995438]
78. Connolly JA. Role of the cytoskeleton in the formation, stabilization, and removal of acetylcholine receptor clusters in cultured muscle cells. *The Journal of cell biology*. 1984; 99:148–54. [PubMed: 6539781]
79. Hall ZW, Lubit BW, Schwartz JH. Cytoplasmic actin in postsynaptic structures at the neuromuscular junction. *The Journal of cell biology*. 1981; 90:789–92. [PubMed: 7026578]
80. Thirunavukarasou A, Govindarajulu G, Singh P, Bandi V, Muthu K, Baluchamy S. Cullin 4A and 4B ubiquitin ligases interact with gamma-tubulin and induce its polyubiquitination. *Molecular and cellular biochemistry*. 2015; 401:219–28. [PubMed: 25542213]
81. Yan J, Yan F, Li Z, Sinnott B, Cappell KM, Yu Y, et al. The 3M complex maintains microtubule and genome integrity. *Molecular cell*. 2014; 54:791–804. [PubMed: 24793695]
82. Starostina NG, Simpliciano JM, McGuirk MA, Kipreos ET. CRL2(LRR-1) targets a CDK inhibitor for cell cycle control in *C. elegans* and actin-based motility regulation in human cells. *Developmental cell*. 2010; 19:753–64. [PubMed: 21074724]
83. Hudson AM, Cooley L. Drosophila Kelch functions with Cullin-3 to organize the ring canal actin cytoskeleton. *The Journal of cell biology*. 2010; 188:29–37. [PubMed: 20065088]
84. Chen Y, Yang Z, Meng M, Zhao Y, Dong N, Yan H, et al. Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. *Molecular cell*. 2009; 35:841–55. [PubMed: 19782033]
85. Skaar JR, Pagan JK, Pagano M. SCF ubiquitin ligase-targeted therapies. *Nature reviews Drug discovery*. 2014; 13:889–903. [PubMed: 25394868]
86. Zheng N, Zhou Q, Wang Z, Wei W. Recent advances in SCF ubiquitin ligase complex: Clinical implications. *Biochimica et biophysica acta*. 2016; 1866:12–22. [PubMed: 27156687]

87. Watson IR, Irwin MS, Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. *Cancer Cell*. 2011; 19:168–76. [PubMed: 21316600]
88. Domenighetti AA, Chu PH, Wu T, Sheikh F, Gokhin DS, Guo LT, et al. Loss of FHL1 induces an age-dependent skeletal muscle myopathy associated with myofibrillar and intermyofibrillar disorganization in mice. *Human molecular genetics*. 2014; 23:209–25. [PubMed: 23975679]
89. Smith LR, Chambers HG, Lieber RL. Reduced satellite cell population may lead to contractures in children with cerebral palsy. *Developmental medicine and child neurology*. 2013; 55:264–70. [PubMed: 23210987]
90. Lange S, Gehmlich K, Lun AS, Blondelle J, Hooper C, Dalton ND, et al. MLP and CARP are linked to chronic PKC α signalling in dilated cardiomyopathy. *Nature communications*. 2016; 7:12120.
91. Rasband, WS. ImageJ. U S National Institutes of Health; Bethesda, Maryland, USA: 1997–2016. <http://imagej.nih.gov/ij/>
92. Zammit PS, Partridge TA, Yablonka-Reuveni Z. The skeletal muscle satellite cell: the stem cell that came in from the cold. *The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society*. 2006; 54:1177–91. [PubMed: 16899758]

Highlights

- Cullin-RING ligases play pivotal roles for terminal skeletal muscle differentiation
- Cullin inhibition blocks myotube formation, entry into the differentiation program
- Cullin inhibition interferes with acetylcholine receptor clustering
- Protein levels of myogenic repressors Bhlhe41, Id1 are controlled by Cullin
- Cullin inhibition may have clinical implications for cancer patients

Figure 1. Cullin E3-ligase activity is required for myotube formation in C2C12 cells

A) Analysis of proteins modified by nedd8 in C2C12 cells during proliferation (Pro), or during differentiation at day 2 and 5. GAPDH is shown to demonstrate equal loading of the samples. B) Quantification of GAPDH normalized nedd8 modified protein levels around 80kDa (from A). C) Quantification of nedd8 mRNA levels, normalized against cyclophilin B. B-C) Sample size and p-values are shown in the figure. D) Representative brightfield images of C2C12 after 5 days in differentiation medium. Cells have been treated with vehicle control (DMSO) or 330nM NAE1 inhibitor MLN4924 from the onset of differentiation. Scale bar = 40µm. E) Representative brightfield images of C2C12 after 5 days in differentiation medium. Cells have been treated with vehicle control (DMSO) or 330nM NAE1 inhibitor MLN4924 one, two or three days after start of differentiation. Scale bar = 40µm. F) Quantification of C2C12 fusion index for C2C12 cells exposed after one, two or three days of differentiation start with 330nM MLN4924, or vehicle control (DMSO). Sample size and p-values are indicated in the figure. G) Percentage of counted myotubes with 2–3, 4–6, 7–10 or more than 11 nuclei per myotube, from C2C12 cultures exposed to

330nM MLN4924 after one, two or three days of differentiation, or vehicle control (DMSO). H) Immunoblot analyses of cullin-1, cullin-3, and nedd8 expression levels of C2C12 cells in proliferation (Pro), or after 5 days in differentiation (Diff) medium with 300nM MLN4924 (+) or vehicle control (DMSO, -). GAPDH was used as loading control.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2. MLN4924 dose-response curve and nedd8 siRNA

A) Immunofluorescence analysis of C2C12 cells differentiated for 5 days in presence of 30nM, 130nM, 230nM or 330nM MLN4924, or vehicle control (DMSO). Cells were stained with an antibody against pan-sarcomeric myosin heavy chain (MyHC). DAPI was used as counterstain. Scale bar = 100µm. B) Quantification of fusion index in response to increasing MLN4924 concentrations. Shown are average fusion indexes, standard errors and p-values (indicated in figure). Grey line indicates fitted curve to determine IC50 value. C) Immunoblot analysis of nedd8 and pan-sarcomeric myosin heavy chain (MyHC) protein levels in total protein samples of C2C12 cells differentiated for 5 days in presence of 30nM, 130nM, 230nM or 330nM MLN4924, or vehicle control (0nM MLN4924; DMSO). GAPDH was used as loading control. D) Immunoblot analysis of nedd8 in C2C12 after 3 days of differentiation. E & F) Immunofluorescence analysis (E) and fusion index (F) of differentiated C2C12 cells transfected with siRNA against nedd8 or scrambled control (CTL). Cells were differentiated for 5 days and stained with an antibody against pan-sarcomeric myosin heavy chain (MyHC). DAPI was used as counterstain. Scale bar = 100µm. Standard errors and p-values are indicated in the figure. G) Immunoblot analysis of

pan-sarcomeric myosin heavy chain (MyHC) in differentiated C2C12 after 5 days. Ponceau (D) or GAPDH (G) were used as loading controls.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 3. MLN4924 inhibits entry into the terminal myogenic differentiation program

A & B) Immunofluorescence analysis of C2C12 cells differentiated for 5 days in presence or absence of 330nM MLN4924, stained with antibodies against sarcomeric myosin heavy chain (MyHC) and desmin (A), or alpha-actinin (B). DAPI was used as counterstain in A and B. Scale bar = 50µm. C) Immunoblot analysis of pan-sarcomeric myosin heavy chain (MyHC) and myogenin expression in whole cell lysates of C2C12 cells either in proliferation (Pro), or after 5 days in differentiation (Diff) medium with 300nM MLN4924 (+) or vehicle control (DMSO, -). GAPDH was used as loading control. D–F) Relative normalized protein levels of nedd8 protein levels (80kDa band, D), myogenin (E) and pan-sarcomeric myosin heavy chain (MyHC, F) in MLN4924 (MLN) treated C2C12 cells five days after differentiation compared to controls (CTL). Three independent samples were run per group; p-values are indicated in the figure.

Figure 4. Cullin E3-ligase activity is required for myotube formation of mouse and human muscle stem cells

A) Immunofluorescence analysis of primary cultures of mouse muscle stem cells after 5 days of differentiation. Cells were differentiated in presence of 330nM MLN4924 or vehicle control (DMSO), and stained with antibodies against desmin and pan-sarcomeric myosin heavy chain (MyHC). DAPI was used as counterstain. Scale bar = 100 μ m. B) Immunoblot analysis of cullin-1 and pan-sarcomeric myosin heavy chain (MyHC) protein levels in total lysates of differentiated primary mouse muscle stem cell cultures, treated with 330nM MLN4924 (+) or vehicle control (DMSO, -). GAPDH and ponceau stained actin band were used as loading controls. C & D) Immunofluorescence analysis of human muscle stem cells after 5 days of differentiation in presence of 330nM MLN4924 or vehicle control (DMSO). Cells were stained with antibodies against slow myosin heavy chain 7 (MyHC; C) or myogenin (D). DAPI and fluorescently labeled WGA were used as counterstains. Scale bar = 100 μ m.

Figure 5. Effect of cullin E3-ligase inhibition on agrin-induced acetylcholine receptor clustering in C2C12 cells

A) Immunofluorescence analysis of agrin treated C2C12 cells 5 days after differentiation, in presence of 330nM MLN4924 or vehicle control (DMSO). Cells were stained with antibodies against pan-sarcomeric myosin heavy chain (MyHC), and fluorescently labeled alpha-bungarotoxin (BTX) to visualize acetylcholine receptors. DAPI was used as counterstain. Scale bar = 50 μm . B–F) Quantitative analysis of myotube length (B), fusion index (nuclei/myotube; C), number of acetylcholine receptor clusters per myotube (D), acetylcholine receptor cluster number per mm^2 (E) and cluster length per mm^2 (F). Shown are averages and standard errors. Sample size and p-values are indicated in the figure.

Figure 6. Effect of cullin E3-ligase inhibition on terminal muscle differentiation are reversible

A) Immunofluorescence analysis of C2C12 cells after ten days of differentiation in vehicle (10d DMSO) supplemented differentiation medium, compared to cells cultured for five days in differentiation medium supplemented with 300nM MLN4924 followed by five days in differentiation medium (5d MLN / 5d diff.). Cells were stained with antibodies against pan-sarcomeric myosin heavy chain (MyHC) and desmin. DAPI was used as counterstain. Scale bar = 100µm. B) Quantitative analysis of fusion index of differentiated C2C12 cells as in (A), compared to average fusion index of differentiated C2C12 cells after five days in culture (5d DMSO-CTL). Shown are averages and standard errors. Sample sizes and p-values are indicated in the figure. C) Immunoblot analysis of whole cell lysates of C2C12 cells differentiated for 5 days with MLN4924, followed by 5 days differentiation medium (5d/5d), compared to MLN4924 treated (MLN) as well as vehicle treated control (CTL, DMSO) cells differentiated for 10 days. Shown are representative immunoblots stained with antibodies against pan-sarcomeric myosin heavy chain (MyHC) and nedd8. GAPDH was used as loading control. D) Quantitative analysis of myosin heavy chain protein levels (as in C).

Figure 7. 5-aza-dC (Aza) partially alleviates the inhibitory effects of MLN4924 on terminal C2C12 differentiation

A) Immunofluorescence of C2C12 cells five days after differentiation in presence of 330nM MLN4924 alone, in combination with 10μM 5-aza-dC (Aza), or vehicle control (DMSO). Cells were stained with an antibody against alpha-actinin (green in overlay). DAPI (blue in overlay) was used as counterstain. Scale bar = 100μm. B) Fraction analysis of nuclei per alpha-actinin positive cells in 330nM MLN4924 (MLN) treated, or 330nM MLN4924 and 10μM Aza treated C2C12 five days after differentiation, compared to vehicle control (CTL/DMSO). Sample size (total counted nuclei) and p-values are indicated in the figure. C) Analysis of alpha-actinin positive cells per mm² in presence of MLN4924 (MLN) alone, in combination with 10μM Aza, or in control (CTL). Sample size of alpha actinin positive cells, and p-values are indicated in the figure. D) Quantitative PCR analysis of relative normalized (against GAPDH) myogenin expression in proliferative C2C12 myoblasts cultures (Pro), compared to C2C12 differentiated for five days in presence of 330nM MLN4924 (MLN) alone, or in combination with 10μM Aza, or vehicle treated control (CTL, DMSO). Sample size (biological replicates) and p-values are indicated in the figure. (n.s. = non-significant). E) Immunoblot analysis of sarcomeric myosin heavy chain (MyHC) and nedd8 protein levels in differentiated C2C12 cells after five days in culture. Samples are total protein lysates of cells treated with 330nM MLN4924 (MLN) alone, or in combination with 10μM Aza. F, G) Fusion index (F) and cluster analysis of nuclei/myotube (G) of 330nM MLN4924 (MLN) treated, or 330nM MLN4924 and 10μM Aza treated C2C12 five days after differentiation, compared to vehicle control (CTL/DMSO). Sample size and p-values (in F) are indicated in the figure.

Figure 8. Analysis of protein degradation of myogenic repressors ZBTB38, Bhlhe41 and Id1

A) Analysis of ZBTB38 protein levels in C2C12 cells during proliferation or 2 days after differentiation in presence of either DMSO (Ctl), 330nM MLN4924 (MLN) or 330nM MLN4924 (MLN) and 10 μ M 5-aza-dC (Aza). Ponceau was used to demonstrate equal loading. Shown are a representative immunoblot (upper panel) and the quantification of protein levels (lower panel). Sample size and p-values are indicated in the figure. B, C) Analysis of protein interaction between cullin-3 and either full length ZBTB38 in a co-immunoprecipitation experiment (B) or the BTB-domain of ZBTB38 only in a GST-pulldown experiment (C) indicates no association between the two proteins. GAPDH and normal rabbit-IgG were used as controls in (B). GST alone was used as control in (C). Abbreviations: IN-Input, FT-flow-through, IP-immunoprecipitate, CTL-control. D) Analysis of subcellular ZBTB38 distribution during proliferation and differentiation at 2 and 5 days of C2C12 cells. Cells were stained with an antibody against ZBTB38, and labeled with DAPI to outline nuclei. Arrows indicate primarily nuclear localized ZBTB38 in proliferative and undifferentiated C2C12 cells, whereas arrowheads point to nuclei of differentiated C2C12 cells. Scale bar = 50 μ m. E) Analysis of Bhlhe41 and Id1 protein levels during proliferation (Pro) and 2 days after onset of differentiation (Diff.) in presence (MLN) or absence (Ctl) of MLN4924. Ponceau staining of total proteins (actin band) was used as loading control.

Figure 9. Cullin requirement in the terminal skeletal muscle differentiation process
Overview of biological steps and developmental milestones for the differentiation from pluripotent progenitor stem cells, to skeletal muscle stem cells (satellite cells), into skeletal muscle myofibers that are anchored by tendons (muscle-tendon unit; MTU). Shown are marker genes and their approximate temporal expression during the differentiation process. Effect of cullin E3-ubiquitin ligase inhibition for each of the differentiation steps is indicated. Figure adapted from [92].